<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04122560</url>
  </required_header>
  <id_info>
    <org_study_id>UMCN-AKF-18.07</org_study_id>
    <nct_id>NCT04122560</nct_id>
  </id_info>
  <brief_title>Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration</brief_title>
  <acronym>FOLIA</acronym>
  <official_title>Fluconazole Pharmacokinetics, Including Bioavailability, in Obese Subjects After an Intravenous and Oral Administration (FOLIA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Radboud University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>St. Antonius Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Radboud University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The pharmacokinetics of fluconazole are expected to be different in obese patients compared&#xD;
      to non-obese patients. The investigators will determine fluconazole and free fluconazole&#xD;
      concentrations in 16 obese patients and 8 healthy volunteers, who will receive oral and&#xD;
      intravenous fluconazole in a semi-simultaneous design.&#xD;
&#xD;
      A full pharmacokinetic curve will be obtained until 48 hours after intravenous&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The pharmacokinetics of fluconazole are expected to be different in obese patients compared&#xD;
      to non-obese patients. Therefore, extrapolation of data from healthy volunteers and is not&#xD;
      possible.&#xD;
&#xD;
      To investigate these differences 16 obese patients and 8 healthy subjects will be studied.&#xD;
&#xD;
      Patients will receive fluconazole by semi-simultaneous design. Blood sampling for&#xD;
      pharmacokinetic analysis will be retrieved through a central venous catheter. A maximum of&#xD;
      100 milliliter blood in total will be drawn for this study. Patients will be monitored daily&#xD;
      during the treatment period for adverse events of the study drug.&#xD;
&#xD;
      Full pharmacokinetic curves will be taken after oral and intravenous administration. This&#xD;
      pharmacokinetic analysis will enable the determination of bioavailability and enable the&#xD;
      determination of intra-individual variability.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">November 30, 2019</start_date>
  <completion_date type="Actual">March 23, 2021</completion_date>
  <primary_completion_date type="Actual">March 23, 2021</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Comparing a 2 groups of obese subjects vs 1 group of non-obese subjects</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of fluconazole</measure>
    <time_frame>48 hours</time_frame>
    <description>The concentration-time curve of fluconazole will be compared with that in non-obese subjects. Exposure is assessed by area-under-the-curve from zero to 48 hours (AUC0-48h)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC) of fluconazole augmented dose</measure>
    <time_frame>48 hours</time_frame>
    <description>The concentration-time curve of fluconazole will be compared with that in non-obese subjects. Exposure is assessed by area-under-the-curve from zero to 48 hours (AUC0-48h)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Fluconazole</condition>
  <condition>Candidiasis</condition>
  <condition>Invasive Fungal Infections</condition>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>Obese subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg&#xD;
Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-obese subjects</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drug: Fluconazole tablet (diflucan) 200mg Single dose by oral administration of 400mg&#xD;
Drug: Fluconazole injection (diflucan) 400mg Single dose by intravenous infusion 400mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole 200mg tab</intervention_name>
    <description>PO dose of 400mg</description>
    <arm_group_label>Non-obese subjects</arm_group_label>
    <arm_group_label>Obese subjects</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fluconazole 2 MG/ML</intervention_name>
    <description>IV dose of 400mg</description>
    <arm_group_label>Non-obese subjects</arm_group_label>
    <arm_group_label>Obese subjects</arm_group_label>
    <other_name>Diflucan</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Subjects BMI:&#xD;
&#xD;
               1. obese groups: subject must have a BMI ≥35 kg/m2 at the time of inclusion or has&#xD;
                  undergone bariatric surgery;&#xD;
&#xD;
               2. non-obese group: subject must have a BMI ≥18.5 and &lt;30 kg/m2 at the time of&#xD;
                  inclusion;&#xD;
&#xD;
          2. Subject is at least 18 of age on the day of screening and not older than 65 years of&#xD;
             age on the day of dosing;&#xD;
&#xD;
          3. Subject able and willing to sign the Informed Consent before screening evaluations.&#xD;
&#xD;
          4. If a woman, is neither pregnant nor able to become pregnant and is not nursing an&#xD;
             infant.&#xD;
&#xD;
             For the non-obese subjects the following additional inclusion criteria applies:&#xD;
&#xD;
          5. Subject is in good age-appropriate health condition as established by medical history,&#xD;
             physical examination, electrocardiography, results of biochemistry and hematology&#xD;
             within 6 weeks prior to study drug administration. Results of biochemistry and&#xD;
             hematology should be within the laboratory's reference ranges (see Appendix A). If&#xD;
             laboratory results are not within the reference ranges, the subject is included based&#xD;
             on the investigator's judgment that the observed deviations are not clinically&#xD;
             relevant. This should be clearly recorded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Documented history of sensitivity to fluconazole or similar azole-compound;&#xD;
&#xD;
          2. Documented history of the long QT syndrome (LQTS);&#xD;
&#xD;
          3. History of, or known abuse of drugs, alcohol or solvents (up until a maximum of three&#xD;
             months before study drug administration);&#xD;
&#xD;
          4. Use of medication that has known relevant interaction with study drug as determined by&#xD;
             the investigator up to 1 weeks prior to study drug administration;&#xD;
&#xD;
          5. Donation of blood or plasma to a blood bank or in a clinical study (except a screening&#xD;
             visit) within 4 weeks prior to study drug administration;&#xD;
&#xD;
          6. Blood transfusion within 8 weeks prior to study drug administration;&#xD;
&#xD;
          7. Treatment with the concerning study drug up to 7 days before administration of the&#xD;
             study drug;&#xD;
&#xD;
          8. Any other sound medical, psychiatric and/or social reason as determined by the&#xD;
             investigator.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>St. Antonius hospital</name>
      <address>
        <city>Nieuwegein</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Radboudumc</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>October 3, 2019</study_first_submitted>
  <study_first_submitted_qc>October 9, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 10, 2019</study_first_posted>
  <last_update_submitted>July 13, 2021</last_update_submitted>
  <last_update_submitted_qc>July 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>fluconazole</keyword>
  <keyword>candidiasis</keyword>
  <keyword>invasive fungal infections</keyword>
  <keyword>mycoses</keyword>
  <keyword>antifungal agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Candidiasis</mesh_term>
    <mesh_term>Mycoses</mesh_term>
    <mesh_term>Invasive Fungal Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fluconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

